Zealand Pharma A/S (ZEAL.CO)

DKK 802.5

(0.44%)

EBITDA Summary of Zealand Pharma A/S

  • Zealand Pharma A/S's latest annual EBITDA in 2023 was -651.58 Million DKK , up 19.89% from previous year.
  • Zealand Pharma A/S's latest quarterly EBITDA in 2024 Q2 was -260.91 Million DKK , down -20.28% from previous quarter.
  • Zealand Pharma A/S reported an annual EBITDA of -884.87 Million DKK in 2022, up 31.7% from previous year.
  • Zealand Pharma A/S reported an annual EBITDA of -729.67 Million DKK in 2021, down -11.71% from previous year.
  • Zealand Pharma A/S reported a quarterly EBITDA of -249.22 Million DKK for 2024 Q1, up 16.98% from previous quarter.
  • Zealand Pharma A/S reported a quarterly EBITDA of -124.98 Million DKK for 2023 Q4, down -268.05% from previous quarter.

Annual EBITDA Chart of Zealand Pharma A/S (2023 - 2007)

Historical Annual EBITDA of Zealand Pharma A/S (2023 - 2007)

Year EBITDA EBITDA Growth
2023 -651.58 Million DKK 19.89%
2022 -884.87 Million DKK 31.7%
2021 -729.67 Million DKK -11.71%
2020 -583.54 Million DKK -54.98%
2019 -559.74 Million DKK 15.9%
2018 -442 Million DKK -171.67%
2017 -250.39 Million DKK -108.24%
2016 -113.21 Million DKK -39.69%
2015 -75.11 Million DKK -26.58%
2014 -64.54 Million DKK 62.14%
2013 -177.76 Million DKK -507.59%
2012 41.69 Million DKK 122.76%
2011 17.5 Million DKK 118.61%
2010 -101.3 Million DKK -45.4%
2009 -72.56 Million DKK -60.93%
2008 -30.19 Million DKK 28.53%
2007 -62.52 Million DKK 0.0%

Peer EBITDA Comparison of Zealand Pharma A/S

Name EBITDA EBITDA Difference
ALK-Abelló A/S 913 Million DKK 171.367%
Bavarian Nordic A/S 2.05 Billion DKK 131.757%
Genmab A/S 5.56 Billion DKK 111.717%
Gubra A/S -28.89 Million DKK -2154.992%
Novo Nordisk A/S 113.33 Billion DKK 100.575%
Orphazyme A/S -26.04 Million DKK -2401.459%
Pharma Equity Group A/S -24.79 Million DKK -2527.445%